Pictet North America Advisors SA Acquires 13,705 Shares of AstraZeneca (AZN)

Pictet North America Advisors SA lifted its holdings in shares of AstraZeneca (NYSE:AZN) by 5.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 278,434 shares of the company’s stock after acquiring an additional 13,705 shares during the period. AstraZeneca makes up approximately 2.9% of Pictet North America Advisors SA’s investment portfolio, making the stock its 9th largest holding. Pictet North America Advisors SA’s holdings in AstraZeneca were worth $19,121,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of AZN. American International Group Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter worth about $1,976,000. Hardman Johnston Global Advisors LLC acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $35,125,000. Two Sigma Investments LP acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $30,768,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of AstraZeneca during the fourth quarter worth about $25,455,000. Finally, Farallon Capital Management LLC lifted its holdings in shares of AstraZeneca by 18.4% during the fourth quarter. Farallon Capital Management LLC now owns 3,765,000 shares of the company’s stock worth $130,646,000 after purchasing an additional 585,000 shares during the period. Institutional investors and hedge funds own 15.18% of the company’s stock.

AZN has been the subject of a number of research reports. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. BMO Capital Markets set a $40.00 target price on AstraZeneca and gave the stock a “buy” rating in a report on Thursday, March 22nd. ValuEngine raised AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Monday, March 19th. Sanford C. Bernstein lifted their target price on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Finally, Leerink Swann reaffirmed a “market perform” rating and set a $36.00 target price (up previously from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.12.

Shares of AstraZeneca opened at $36.40 on Monday, Marketbeat Ratings reports. AstraZeneca has a 12-month low of $28.43 and a 12-month high of $36.75. The company has a market capitalization of $92.20 billion, a price-to-earnings ratio of 8.50, a P/E/G ratio of 1.93 and a beta of 0.61. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply